Sunday, 24 May 2026
  
Login

Australia's most trusted
source of pharma news

Sunday, 24 May 2026
News

Second 'no' for breast cancer drug

Posted 27 March 2025 AM

AstraZeneca has officially been delivered a double blow for its hyped breast cancer treatment Truqap with MSAC following the PBAC in knocking back a co-dependent submission.

Truqap, formerly known as capivasertib became the first AKT inhibitor approved by the TGA last year in combination with fulvestrant (commonly known as AstraZeneca’s Faslodex) for the treatment of adults with HR+/HER2- locally advanced or metastatic breast cancer following recurrence or progression on or after an endocrine based regimen.

To see the whole article, please login

Popular

High-flyer exits corporate world
New CEO announced after 2 years
Drug pulled after less than 3 years
Ex-Google boss busts pharma silos
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home